The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery

Purpose: Oligonucleotide (ON) therapeutics—antisense ONs, siRNA, miRNA mimics/inhibitors, antimiRs—are limited by poor membrane permeability, rapid renal/RES clearance, and nuclease degradation. LNPs can protect ONs and improve delivery, but the role of helper lipids in LNP stability, circulation, endosomal escape, and in vivo performance remains insufficiently understood.

Hypothesis: If helper lipids are selected and balanced appropriately in cationic-lipid LNPs—using fusogenic, stabilizing, PEGylating, and/or pH-sensitive lipids—then LNPs can simultaneously maintain colloidal stability and long circulation, facilitate cellular uptake, promote endosomal release of ON cargo, and improve in vivo oligonucleotide delivery.

Aims: Review the roles of helper lipids in LNPs designed for ON delivery. - Discuss key helper lipid classes: DOPE, cholesterol, phosphatidylcholines, PEGylating lipids, anionic/pH-sensitive lipids, and other helper lipids. - Describe rational design of LNP composition, including stability vs endosomal release trade-offs. - Highlight examples of clinically translated LNP formulations: SNALPs and Smarticles. - Discuss biodistribution, immunogenicity, and the influence of ON cargo chemistry.

Delivery system: Platform: lipid nanoparticles (LNPs) for oligonucleotide delivery, typically containing a cationic lipid plus helper lipids. - Payloads: antisense ONs, siRNA, miRNA mimics, antimiRs, aptamers, ribozymes, CpG immunostimulatory ONs. - Cationic lipids: DOTMA, DOTAP, DODMA, DLinDMA, DLin-KC2-DMA. - Helper lipids: DOPE; cholesterol; phosphatidylcholines (DSPC, HSPC, egg PC, DOPC); PEG-lipids (mPEG-DSPE, PEG-C-DMA, TPGS, Tween-80, PEG-CHOL); anionic/pH-sensitive lipids (oleic acid, linoleic acid, CHEMS, phosphatidylglycerol); nonionic surfactants (diolein, monooleoyl glycerol, Span80, triolein). - Synthesis: ethanol/acidic pH mixing with ON, followed by dialysis/diafiltration and pH neutralization; PEG-lipid content and lipid/ON ratio control size. - Examples: SNALPs (stable nucleic acid lipid particles); Smarticles (pH-sensitive amphoteric liposomes). - Targeting ligands: antibodies, transferrin, folate, cyclo-RGD, phage-derived peptides.

Approach: Review and synthesis of in vitro, in vivo, and clinical literature. Cited models include mice, guinea pigs, non-human primates, tumor xenografts, and clinical trials (TKM-Ebola, TKM-HBV, TKM-PLK1, PNT2258, MRX34). Disease contexts include Ebola, hepatitis B, cancer, and solid tumors/hematological malignancies. As a review, it reports no primary experimental groups, n values, doses, or controls.

Key methods: No primary methods. The review discusses data generated by cited studies using: - Particle size and zeta potential measurements. - Encapsulation efficiency and LNP stability testing. - In vitro transfection/gene silencing and cytotoxicity assays. - In vivo biodistribution, circulation time, and therapeutic efficacy. - Cytokine induction and immunogenicity assessment. - Clinical trial safety and efficacy readouts.

Key results: SNALPs: DLinDMA/CHOL/DSPC/PEG-C-DMA at 48:20:2:30 molar ratio; size 71–84 nm; complete protection against viremia and death in guinea pigs challenged with Ebola. However, a Phase II trial of TKM-Ebola-Guinea failed to show overall therapeutic benefit. - Other SNALP-siRNAs: PLK1- and KSP-targeting SNALPs given to mice at 2 mg/kg greatly increased survival of tumor-bearing mice. - Smarticles/PNT2258: POPC/DOPE/CHEMS/MO-CHOL at 6:24:23:47 molar ratio; negative zeta potential −40 mV; no PEG-lipid; pH-sensitive due to MO-CHOL and CHEMS; entered clinical trials for non-Hodgkin’s lymphoma. - MRX34: Smarticle-based miRNA-34 mimic; first miRNA mimic to enter clinical trials (Phase I in solid tumors and hematological malignancies). - DOPE: cone-shaped, fusogenic, promotes hexagonal II phase and endosomal release; but DOPE-based LNPs have lower colloidal stability and may be less suitable for ONs than for plasmid DNA. - Cholesterol: fills bilayer gaps, improves serum stability, promotes membrane fusion; as a co-lipid in vivo often outperformed DOPE. - Phosphatidylcholines: cylindrical geometry stabilizes bilayers; DSPC/CHOL used in SNALPs; unsaturated PCs such as DOPC may balance stability and transfection. - PEGylation: improves colloidal stability and circulation but can reduce uptake and endosomal release; low PEG (1–2 mol%) or exchangeable PEG-C-DMA can mitigate this. - Anionic pH-sensitive lipids: oleic acid, linoleic acid, CHEMS can confer pH-responsive charge and promote endosomal release. - In vitro vs in vivo: generally poor correlation; in vitro favors high zeta potential and fusogenic lipids, while in vivo requires low zeta potential, PC/CHOL/PEG stabilization, and long circulation.

Interpretation: The authors conclude that helper lipids are critical determinants of LNP stability, circulation, biodistribution, and endosomal release. LNP design requires balancing opposing needs: stability in blood vs destabilization inside endosomes; long circulation vs efficient cellular uptake; low toxicity vs high delivery efficiency. They argue that no single formulation is optimal for all ONs or applications, and that customized design and empirical optimization are required.

Limitations: Review article; no primary data, effect sizes, n values, doses, or controls. - In vitro LNP activity does not reliably predict in vivo performance. - Helper lipid choice must balance stability, circulation, uptake, endosomal escape, toxicity, and immunogenicity. - Cationic lipids can be cytotoxic and immunostimulatory; PEGylation can reduce uptake and cause anti-PEG responses. - ON chemistry (length, single- vs double-stranded, chemical modifications, cholesterol conjugation) affects optimal LNP formulation. - Many cationic lipids are proprietary; formulation optimization is empirical. - Clinical translation remains limited; e.g., TKM-Ebola Phase II failed despite preclinical protection. - LNP complexity may impede scalable manufacturing and regulatory approval.